Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06409689
Other study ID # S058
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2024
Est. completion date July 1, 2025

Study information

Verified date May 2024
Source Tongji Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Identifying the lowest effective opioid dose that achieves rapid pain relief while minimizing side effects is a principal objective in postoperative multimodal analgesia strategies. This study aims to determine the optimal analgesic regimen and dosage by assessing the clinical efficacy of oliceridine for postoperative pain management. It also evaluates oliceridine's contribution to accelerated postoperative recovery, examining aspects such as postoperative pulmonary complications, gastrointestinal function, nausea and vomiting, cognitive function, and emotional distress. Furthermore, the study integrates microbiomics and metabolomics to investigate the underlying molecular mechanisms by which oliceridine promotes rapid postoperative recovery. This research will broaden the clinical data and potential applications of oliceridine, addressing gaps in the field and enhancing practical knowledge. Moreover, this is the first time a clinical study combining multiple omics approaches will provide a comprehensive theoretical foundation for its clinical benefits.


Description:

This study selects 80 elective patients slated for upper abdominal laparoscopic surgery under general anesthesia, classified as ASA I-II. These patients are randomly allocated into four groups: Oliceridine low dose (OⅠ), medium dose (OⅡ), and high dose (OⅢ), and a Morphine (M) group. The postoperative analgesic protocol includes a universal loading dose of 1.5 mg for all groups. Depending on the group, the PCA doses are set at 0.1 mg, 0.35 mg, or 0.5 mg, with a lockout interval of 6 minutes. After the initial dose, patients may receive an additional 0.75 mg per hour as needed, with a daily ceiling of 27 mg for Oliceridine. In the Morphine group, the loading dose is 4 mg with a PCA dose of 1 mg and similar lockout, allowing 2 mg per hour post-loading, capped at 60 mg daily. Outcomes to monitor include systolic and diastolic blood pressures, heart rate, oxygen saturation, and respiratory rate at 6, 24, and 48 hours postoperatively; pain levels using the NRS scale; nausea and vomiting via the VAS score; and pulmonary complications evaluated by EPCO standards at specified intervals. Gastrointestinal function is assessed using the I-FEED score, and mental health through the HADS scale preoperatively and 48 hours post-surgery. Cognitive function is evaluated using the MMSE scale preoperatively and 72 hours postoperatively. Patient fecal samples are collected pre- and 48 hours post-surgery for microbial and metabolomic analyses to identify potential molecular benefits of Oliceridine, informed by its G-protein biased pharmacology. The study also uses statistical methods to compare microbiological outcomes and correlate these with clinical presentations.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date July 1, 2025
Est. primary completion date June 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. ASA grades 1-2 2. Age > 18 years and < 70 years 3. Laparoscopic upper abdominal surgery under general anesthesia is planned, and the operation time is not more than 4 hours 4. Voluntarily receive postoperative controlled intravenous analgesia 5. Subjects understand and can cooperate with this study 6. Subjects can provide and sign written informed consent prior to conducting investigation-related screening procedures Exclusion Criteria: 1. BMI>30 kg/m2 or < 19 kg/m2 2. Patients with preoperative use of opioids, acute and chronic pain or hyperalgesia 3. Patients with coronary atherosclerotic heart disease, significant ischemic heart disease, severe angina, heart failure, valvular disease or other heart disease 4. More severe hepatic and renal insufficiency 5. A history of mental illness or alcoholism 6. A history of alcohol or drug abuse 7. Combined with cranial pressure, intraocular pressure or glaucoma 8. Poorly controlled or untreated hypertension before surgery 9. Preeclampsia or eclampsia 10. Untreated and undertreated hyperthyroidism 11. Combined with autoimmune disease 12. Unable to use the numerical rating scale 13. History of chronic cough 14. Surgery is expected to take more than 4 hours Patients enrolled in other clinical trials within 3 months

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oliceridine fumarate low dose
The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.1 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
Oliceridine fumarate high dose
The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.5 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
Oliceridine fumarate moderate dose
The first loading dose of oliceridine fumarate was 1.5 mg in all patients after operation. The PCA dose of the patients was 0.35 mg, and the locking interval was 6 min. A supplemental dose of 0.75 mg is allowed once per hour as needed after 1 h of the load dose
morphine
The first loading dose of morphine was 4 mg in all patients after operation. The PCA dose of the patients was 1 mg, and the locking interval was 6 min. A supplemental dose of 2 mg is allowed once per hour as needed after 1 h of the load dose; The maximum cumulative daily dose is 60 mg.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Tongji Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary postoperative pain score The NRS Numerical Pain Evaluation Scale assessed postoperative pain status: no pain (0), mild pain (1-3), moderate pain (4-6), and severe pain (7-10). 6 hour, 24hour, and 48 hour after surgery
Secondary Postoperative nausea and vomiting With a 10cm ruler as the scale, 0 at one end indicates no nausea and vomiting, and 10 at the other end indicates the most severe nausea and vomiting that is unbearable. 1 to 4 is mild, 5 to 6 is moderate, 7 to 10 is severe 6 hour, 24 hour, and 48 hour after surgery
Secondary Postoperative pulmonary complications european perioperative clinical outcome (EPCO) 24 hour,72 hour after surgery
Secondary Postoperative cognitive function (mini-mental state examination, MMSE) scale score,The maximum score is 30 points. The classification of dementia is related to the level of education, so if the elderly are illiterate and less than 17 points, primary school and less than 20 points, secondary school and above less than 24 points, then dementia. Before surgery, 3 days after surgery
Secondary Flora abundance Feces were collected from patients before surgery and 48 hours after surgery (stored at negative 80 degrees), and the fecal intestinal flora abundance of patients in each group was determined by 16S rRNA omics One day before surgery and 48 hours after surgery
See also
  Status Clinical Trial Phase
Completed NCT05023850 - Comparing Thoracolumbar Interfascial Plane Block With Erector Spinae Plane Block N/A
Completed NCT06205199 - Analgesic Effect of Ropivacaine Combined With Hydromorphone for CSEA After Total Knee Arthroplasty N/A
Not yet recruiting NCT06062550 - Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery Phase 4
Completed NCT03239314 - Analgesic Effect of Adductor Canal Block With and Without Dexamethasone for Knee Arthroscopy N/A
Completed NCT05317572 - Comparison of Three Different Doses of Intrathecal Morphine for Analgesia After Cesarean Section N/A
Recruiting NCT06157359 - Effect of SNB on the QoR in Patients Undergoing Supratentorial Tumor Resection N/A
Completed NCT03258255 - Analgesic Efficiency of Pudendal Nerve Block Versus Penil Block for Circumsion in Children N/A
Recruiting NCT06430112 - Liposomal Bupivacaine vs Ropivacaine for TAPBs Phase 3
Recruiting NCT06078241 - Postoperative Analgesia in Patients Undergoing Percutaneous Nephrolithotomy N/A
Completed NCT04579302 - Serratus Anterior Block and Erector Spinae Block in Postoperative Analgesia N/A
Completed NCT04111848 - Magnesium and Ketamine in Postoperative Analgesia Phase 4
Completed NCT03341234 - Superficial Serratus Plane Block for Modified Radical Mastectomy and Axillary Lymph Node Disection N/A
Recruiting NCT03540537 - A Trial Comparing Quadratus Lumborum Block (QLB) and Paravertebral Block (PVTB) for Postoperative Analgesia in Hepatectomy N/A
Terminated NCT02150161 - Opioid vs. Opioid-free Anesthesia for Hip Arthroscopy Phase 3
Not yet recruiting NCT01589354 - Effectiveness of Interscalene Brachial Plexus Block and Intra-articular Injection of Ropivacaine for Post-operative Analgesia in Arthroscopic Shoulder Stabilization Surgery N/A
Completed NCT05855798 - Ketamine and Magnesium in Erector Spinae Plane Block Phase 4
Not yet recruiting NCT04845711 - Ultrasound Guided Erector Spinae Plane Block Versus Quadratus Lumborum Block in Laparoscopic Cholecystectomy N/A
Completed NCT03131375 - Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia Phase 2/Phase 3
Completed NCT03885427 - Analgo-Sedative Effects Of Oral, Or Nebulized Ketamine In Pre-schoolers Undergoing Elective Surgery. Early Phase 1
Completed NCT04738357 - A Clinical Study to Evaluate Efficacy and Safety of HSK21542 for Postoperative Analgesia of Subjects Undergoing Elective Laparoscopic Surgery Under General Anesthesia Phase 3